A Day in the Life of an HIV Treater: Overcoming Common Challenges in Practice

Target Audience

The educational design of this activity addresses the needs of US-based HIV-treating physicians, nurse practitioners, physician assistants, nurses, and pharmacists.

Program Overview

HIV treaters must be prepared to see a diverse set of patients and address multiple topics during their clinic day. In this activity, learners will enter a virtual environment to follow Dr. Onyema Ogbuagu through a morning of meetings and appointments that includes discussing cardiovascular disease, initiating rapid antiretroviral therapy (ART), consulting with other clinicians about heavily treatment-experienced (HTE) patients with multidrug resistance (MDR), and engaging in a training session about long-acting injectables (LAI) led by Dr. Bailey Thayer.

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Optimize workflow protocols to administer LAI ART to eligible patients
2. Describe appropriate management of comorbidities in patients with HIV, including ART-regimen modification or initiation of treatment for relevant conditions
3. Educate newly diagnosed patients about HIV, undetectable = untransmittable (U=U), and available ART regimens
4. Develop subsequent treatment regimens for patients experiencing virologic failure, including those for HTE patients with MDR

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Reciprocity Statement

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Integritas Communications. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacist Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs). (Universal Activity Number - JA0007169-9999-26-011-H02-P). This is an application-based activity.

Integritas Contact Information

For more information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com. 

Global Contact Information

For information about the joint accreditation (ACPE credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the activity, application for credit and evaluation form. Participants must also score at least 70% on the post-test. Pharmacists must check CPE monitor for their credit within 60 days of activity completion. Credit cannot be claimed after 60 days.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Integritas and Global adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Integritas and Global are required to disclose all financial relationships with any ineligible company within the past 24 months.  All financial relationships reported are appropriately identified as relevant by Integritas and Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners. 

The faculty have the following relevant financial relationships with ineligible companies:

Onyema Ogbuagu, MBBCh, FACP, FIDSA: Advisory Board: Gilead Sciences, Inc.; ViiV Healthcare

Bailey Thayer, PharmD, AAHIVP, BCIDP: Nothing to disclose

The planners and managers at Integritas Communications and Global have no relevant financial relationships to disclose.

The following planners and managers have no relevant financial relationships with ineligible companies to disclose:

• Emily Shafer, PharmD, MS, RPh (Pharmacist Planner)

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integritas and Global do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.